In addition, analysis of the transcriptional profile of CD34+ cells derived from CML patients treated with imatinib showed a regulation of the canonical FOXO target genes, including p57/CDKN1C and BCL6, suggesting that activation of FOXOs upon TKI treatment also occurs in humans in vivo. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.